Dosage Forms

Vince Russell is director of Respiratory Discovery at Aptuit, www.aptuit.com/drug-design-and-discovery/therapeutic-areas/respiratory.Â 

Articles

Pulmonary drug delivery is becoming increasingly used. When developing pulmonary drugs, pharmaceutical chemists must consider drug absorption, control of particle size, suitable toxicology models, and patient compliance. The author reviews the issues specific to developing drugs designed for pulmonary delivery and considers how-with the right knowledge and expertise-these challenges can be overcome.

Four Challenges for Pulmonary Drug Delivery

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Sensors and communication capability support proper usage, improve compliance, and may enable telemedicine. 

Smart Inhalers Improve Patient Compliance

The Thermo Scientific Pharma mini implant line is built around the Thermo Scientific Pharma mini HME twin-screw micro compounder.


Lab Line Is Designed for Developing Drug Implant Technology

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Characterization of the product and process is key for process development and scale-up of topical drug manufacturing using a QbD approach.

Using QbD in Topical Drug Manufacturing

Agnes Shanley is senior editor of Pharmaceutical Technology.

Successful development requires coordinating and aligning drug and device design, focusing on a complete drug delivery system that meets patients’ needs.

Taking a Systems Approach to Inhalation Therapy Development

The agency recommended a total of 11 drugs at its July meeting, including five orphan drugs. 


EMA Recommends Five Orphan Drugs

SOBI003 is a chemically modified variant of a recombinant human sulfamidase product candidate, using Sobi’s proprietary glycan modification technology.

SOBI003 Granted Orphan Drug Designation for MPS IIIA Treatment

ADV7103 is being evaluated in a Phase III trial in Europe in children and adults with distal renal tubulopathy acidosis. Results from the study are expected in the coming months.

EU Grants Orphan Drug Designation to ADV7103 for Treatment of Distal Renal Tubulopathy Acidosis

The agency announced a plan to eliminate its existing orphan designation request backlog.


FDA to Eliminate Backlog of Orphan Drug Designation Requests

Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York. 

Specialty Dosage Drugs